The Outcome of Acute Lymphoblastic Leukemia in 109 Adult Iraqi Patients

被引:0
作者
Dyna Jaza Mohammed
Sana Dlawar Jalal
Ahmed Khudair Yassin
Ali Ibrahim Mohammed
Nasir Abdulsalam Al-Allawi
机构
[1] Hewa Hemato-onology Hospital,Department of Hematology
[2] University of Sulaimani,Department of Pathology, College of Medicine
[3] Hawler Medical University,Department of Medicine, College of Medicine
[4] University of Duhok,Department of Pathology, College of Medicine
来源
Indian Journal of Hematology and Blood Transfusion | 2021年 / 37卷
关键词
Acute lymphoblastic leukemia; Adults; Survival; Outcome; Iraq;
D O I
暂无
中图分类号
学科分类号
摘要
While many studies addressed the outcome of adult ALL in developed Western countries, there is paucity of such prospective studies from developing Mediterranean ones. This is a prospective cohort study conducted at Hiwa Cancer Hospital in Sulaimani city and Nanakali Hospital in Erbil city-Kurdistan Iraq from March 2012 to August 2017. The main characteristics of adult ALL patients, type of therapy and risk factors were analyzed to assess their impact on treatment outcome and survival status. A total of 109 adult ALL patients were included with a median age of 24 years and male to female ratio of 1.7:1. B-ALL accounted for 76.1% of the cases, while the rest were T-ALL. BCR-ABL rearrangement was encountered in 12% of B-ALL. Complete remission (CR) rate was 81.7%, the overall 5 year survival (OS) was 38%, Relapse Free 5 year Survival (RFS) was 49%. Younger adults (< 35 years) had significantly higher CR rates and OS compared to the older group (P < 0.001 each). On the other hand, gender, high leucocyte count ≥ 50×109/L, immunophenotype (including B and T ALL subtypes), and clinical risk status did not predict a poor outcome. Multivariate analysis revealed that only age < 35 years and BCR-ABL rearrangement were significantly associated with better OS. Despite some limitations, the outcomes of Iraqi adult ALL is comparable to those reported in Western developed countries, with particularly favorable outcomes in younger patients. The need to improve outcome in adult ALL remains an important priority in our country as it is throughout the world.
引用
收藏
页码:264 / 270
页数:6
相关论文
共 188 条
  • [1] Katz AJ(2015)Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden Cancer Causes Control 26 1627-1642
  • [2] Chia VM(2010)Prognostic significance in adult acute lymphoblastic leukemia Br J Haematol 150 389-405
  • [3] Schoonen WM(2015)Analysis of clinical-biological features of adult acute lymphoblastic leukemia(ALL) Gac Med Mex 151 136-144
  • [4] Kelsh MA(2005)Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALLXII/ECOG E2993 Blood 106 3760-3767
  • [5] Rowe JM(2017)Immunophynotypic aberrancies in acute lymphoblastic leukemia from 282 Iraqi patients Int J Lab Hematol 39 625-632
  • [6] Ruiz RD(2011)Outcome of adult patients with acute lymphoblastic leukemia receiving the MRC UKALL XII protocol: a tertiary care center experience Singapore Med J 52 370-374
  • [7] Lopez LA(2000)Results of treatment with HyperCVAD, a dose-intensive regimens, in adult acute lymphoblastic leukemia J Clin Oncol 18 547-561
  • [8] Ruiz AV(2012)Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial Br J Hematol 157 463-471
  • [9] Garcés-Ruiz O(2009)Long term outcome of adult acute lymphoblastic leukemia in Lebanon: a single institution experience from the American University of Beirut Hematol Oncol Stem Cell Ther 2 333-339
  • [10] Nava-Zavala A(2010)Prognostic factors of adult acute lymphoblastic leukemia and their impact on treatment outcome and long term survival Pan Arab J Oncol 3 30-35